---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-271055"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2026-06-15T20:02:48+00:00"
generated_at: "2026-06-15T20:04:16.996674+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics shareholders approve 7M share increase to stock plan at annual meeting

## Summary
- Stockholders approved 3rd A&R 2022 Stock Plan adding 7M shares; votes: 46.6M for, 14.3M against (26.1M broker non-votes).
- Directors Epstein, Jooss, Hamill re-elected with 59.3M, 59.7M, 60.9M votes for, respectively.
- Ernst & Young ratified as independent auditor for FY2026; 86.6M for, 0.3M against.
- Non-binding advisory vote on executive compensation passed with 59.2M for, 1.8M against.

## SEC filing metadata
- accession: 0001193125-26-271055
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2026-06-15T20:02:48+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312526271055/0001193125-26-271055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312526271055/fate-20260612.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-271055
- JSON: https://secwatch.observer/filing/0001193125-26-271055.json
- Plain text: https://secwatch.observer/filing/0001193125-26-271055.txt

## Key facts
- Shareholder Votes
  FATE THERAPEUTICS INC shareholders approved Election of Class I Directors at the 2026-06-12 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-12
  source text: (i) Election of Class I Directors. Director Nominee For Withheld Broker Non-Votes Robert S. Epstein, M.D., M.S. 59,332,820 1,717,842 26,083,760 Karin Jooss, Ph.D. 59,655,584 1,395,078 26,083,760 Laura J. Hamill 60,850,004 200,658 26,083,760
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000119312526271055/0001193125-26-271055-index.htm
- Shareholder Votes
  FATE THERAPEUTICS INC shareholders approved Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-12 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-12
  source text: (ii) Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. For Against Abstain Broker Non-Votes 86,552,927 308,582 272,913 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000119312526271055/0001193125-26-271055-index.htm
- Shareholder Votes
  FATE THERAPEUTICS INC shareholders approved Non-binding advisory vote on the compensation of the Company’s named executive officers at the 2026-06-12 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-12
  source text: (iii) Non-binding advisory vote on the compensation of the Company’s named executive officers. For Against Abstain Broker Non-Votes 59,168,689 1,808,669 73,304 26,083,760
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000119312526271055/0001193125-26-271055-index.htm
- Shareholder Votes
  FATE THERAPEUTICS INC shareholders approved Approval of an amendment to the Amended and Restated 2022 Stock Option and Incentive Plan to increase the number of shares of Common Stock reserved for issuance by 7,000,000 shares at the 2026-06-12 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2026-06-12
  source text: (iv) Approval of an amendment and restatement of the 2022 A&R Plan to increase the number of shares of Common Stock reserved for issuance thereunder. For Against Abstain Broker Non-Votes 46,645,607 14,304,810 100,245 26,083,760
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000119312526271055/0001193125-26-271055-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.